Andrew Partridge
Corporate Officer/Principal presso TURG POIN
Posizioni attive di Andrew Partridge
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| TURG POIN | Corporate Officer/Principal | 13/07/2020 | - |
Storia della carriera di Andrew Partridge
Precedenti posizioni note di Andrew Partridge
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| CENTREXION THERAPEUTICS CORPORATION | Corporate Officer/Principal | 24/09/2018 | 02/07/2020 |
| VERTEX PHARMACEUTICALS INCORPORATED | Corporate Officer/Principal | 01/01/2013 | 01/11/2018 |
| AMGEN INC. | Vendite & Marketing | 01/01/2003 | 01/01/2013 |
Statistiche
Distribuzione geografica
| Stati Uniti | 5 |
Posizioni
| Corporate Officer/Principal | 3 |
| Sales & Marketing | 1 |
Settori
| Health Technology | 5 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| VERTEX PHARMACEUTICALS INCORPORATED | Health Technology |
| AMGEN INC. | Health Technology |
| Aziende private | 2 |
|---|---|
Centrexion Therapeutics Corp.
 Centrexion Therapeutics Corp. Pharmaceuticals: MajorHealth Technology Centrexion Therapeutics Corp. is a clinical-stage biopharmaceutical company, which engages in identifying, developing, and commercializing novel, non-opioid, and non-addictive therapies to address the large unmet medical need for the treatment of chronic pain. Its product pipeline includes CNTX-4975, CNTX-0290, CNTX-6970, CNTX-2022, CNTX-6016, and intrathecal platform. The company was founded by Sol J. Barer and Jeffrey B. Kindler in February 2013 and is headquartered in Boston, MA. | Health Technology |
Turning Point Therapeutics, Inc.
 Turning Point Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Turning Point Therapeutics, Inc. is a clinical-stage oncology biopharmaceutical company, which engages in designing and developing next-generation therapies that target genetic drivers of cancer to improve the lives of patients. Its product pipeline include Repotrectinib, TPX-0022, TPX-0046, and TPS-O131, a next-gen ALK inhibitor. The company was founded by Jingrong Jean Cui and Y. Peter Li in October 2013 and is headquartered in San Diego, CA. | Health Technology |
- Borsa valori
- Insiders
- Andrew Partridge
- Esperienza
